Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

被引：1
|
作者：
Yoroidaka, Takeshi [1 ,2 ]
Takamatsu, Hiroyuki [1 ]
Yamashita, Takeshi [3 ]
Murata, Ryoichi [3 ]
Yoshihara, Kyoko [4 ]
Yoshihara, Satoshi [4 ]
Ueda, Mikio [3 ]
Nakao, Shinji [1 ]
Matsue, Kosei [5 ]
机构：
[1] Kanazawa Univ, Dept Hematol, Kanazawa, Ishikawa, Japan
[2] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
[3] Keiju Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa, Japan
[4] Hyogo Coll Med, Dept Hematol, Nishinomiya, Hyogo, Japan
[5] Kameda Med Ctr, Div Hematol Oncol, Dept Med, Kamogawa, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3130
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Minimal residual disease assessment using EuroFlow in patients with relapsed/refractory multiple myeloma who received carfilzomib plus lenalidomide plus dexamethasone (KRD) therapy
    Takamatsu, Hiroyuki
    Yoroidaka, Takeshi
    Yamashita, Takeshi
    Murata, Ryoichi
    Yoshihara, Kyoko
    Yoshihara, Satoshi
    Ueda, Mikio
    Nakao, Shinji
    Matsue, Kosei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E184 - E184
  • [2] Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone
    Yoroidaka, Takeshi
    Yamashita, Takeshi
    Murata, Ryoichi
    Yoshihara, Kyoko
    Yoshihara, Satoshi
    Ueda, Mikio
    Nakao, Shinji
    Matsue, Kosei
    Takamatsu, Hiroyuki
    ANTICANCER RESEARCH, 2023, 43 (01) : 157 - 165
  • [3] Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone
    Mailankody, Sham
    Korde, Neha
    Faham, Malek
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Weng, Li
    Moorhead, Martin
    Costello, Rene
    Zhang, Yong
    Zingone, Adriana
    Burton, Debbie
    Wu, Peter
    Mulquin, Marcia
    Zuchlinski, Diamond
    Kurlander, Roger
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Roschewski, Mark
    Landgren, Ola
    BLOOD, 2013, 122 (21)
  • [4] Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)
    Jasielec, Jagoda
    Dytfeld, Dominik
    Griffith, Kent A.
    McDonnell, Kathryn
    Lebovic, Daniel
    Kandarpa, Malathi
    Anderson, Tara
    Mietzel, Melissa
    Faham, Malek
    Lee, Liana
    Levy, Joan
    Alonge, Mattina
    Rosebeck, Shaun
    Kaminski, Mark
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [5] RAPID AND PERSISTENT EFFICACY OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) IN AGGRESSIVE MULTIPLE MYELOMA DISEASE
    Garibaldi, B.
    Condorelli, A.
    Romano, A.
    Del Fabro, V.
    Elia, F.
    Di Raimondo, F.
    Conticello, C.
    HAEMATOLOGICA, 2021, 106 (10) : 168 - 169
  • [6] DRESS syndrome after KRd (carfilzomib, lenalidomide, dexamethasone) therapy in a patient with multiple myeloma
    Gajewska, Malgorzata
    Terlikowska-Brzosko, Agnieszka
    Sawicki, Waldemar
    Wrobel, Katarzyna
    Lorent, Malgorzata
    Rzepecki, Piotr
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (10):
  • [7] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [8] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    Blood Cancer Journal, 13
  • [9] Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
    Landgren, Ola
    Alsina, Melissa
    Biran, Noa
    Vesole, David H.
    Wallace, Paul K.
    Fang, Belle
    Arnold, Gregory
    Kimball, Amy
    Siegel, David S.
    BLOOD, 2020, 136
  • [10] Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
    Garcia-Guinon, Antoni
    Charry, Paola Andrea
    Jimenez, Maria
    Sarra, Josep
    Delgado, Izarbe
    de la Torre, Laura Segura
    Santaliestra, Marta
    Garcia-Pintos, Marta
    Gonzalez, Yolanda
    Senin, Alicia
    Motllo, Cristina
    Abella, Eugenia
    Cabezudo, Elena
    Granell, Miquel
    Sancho, Esther
    Herranz, Maria Jose
    Seres, Yasmina
    Gironella, Mercedes
    Soler, Juan Alfons
    Marti-Tutusaus, Josep Maria
    Ben Azaiz, Ran
    de Larrea, Carlos Fernandez
    ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1177 - 1186
12345